These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 28627871)

  • 1. The Sulfur-Linked Analogue of O-GlcNAc (S-GlcNAc) Is an Enzymatically Stable and Reasonable Structural Surrogate for O-GlcNAc at the Peptide and Protein Levels.
    De Leon CA; Levine PM; Craven TW; Pratt MR
    Biochemistry; 2017 Jul; 56(27):3507-3517. PubMed ID: 28627871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic recoding to dissect the roles of site-specific protein O-GlcNAcylation.
    Gorelik A; Bartual SG; Borodkin VS; Varghese J; Ferenbach AT; van Aalten DMF
    Nat Struct Mol Biol; 2019 Nov; 26(11):1071-1077. PubMed ID: 31695185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. O-GlcNAc modification inhibits the calpain-mediated cleavage of α-synuclein.
    Levine PM; De Leon CA; Galesic A; Balana A; Marotta NP; Lewis YE; Pratt MR
    Bioorg Med Chem; 2017 Sep; 25(18):4977-4982. PubMed ID: 28487126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in O-Linked N-Acetylglucosamine (O-GlcNAc) Homeostasis Activate the p53 Pathway in Ovarian Cancer Cells.
    de Queiroz RM; Madan R; Chien J; Dias WB; Slawson C
    J Biol Chem; 2016 Sep; 291(36):18897-914. PubMed ID: 27402830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The O-GlcNAc Modification of Recombinant Tau Protein and Characterization of the O-GlcNAc Pattern for Functional Study.
    El Hajjar L; Bridot C; Nguyen M; Cantrelle FX; Landrieu I; Smet-Nocca C
    Methods Mol Biol; 2024; 2754():237-269. PubMed ID: 38512671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. '
    Zhao L; Shah JA; Cai Y; Jin J
    Molecules; 2018 Aug; 23(8):. PubMed ID: 30082668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Measuring O-GlcNAc cleavage by OGA and cell lysates on a peptide microarray.
    Sharif S; Shi J; Bourakba M; Ruijtenbeek R; Pieters RJ
    Anal Biochem; 2017 Sep; 532():12-18. PubMed ID: 28571750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Developmental regulation of protein O-GlcNAcylation, O-GlcNAc transferase, and O-GlcNAcase in mammalian brain.
    Liu Y; Li X; Yu Y; Shi J; Liang Z; Run X; Li Y; Dai CL; Grundke-Iqbal I; Iqbal K; Liu F; Gong CX
    PLoS One; 2012; 7(8):e43724. PubMed ID: 22928023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insights into O-linked N-acetylglucosamine ([0-9]O-GlcNAc) processing and dynamics through kinetic analysis of O-GlcNAc transferase and O-GlcNAcase activity on protein substrates.
    Shen DL; Gloster TM; Yuzwa SA; Vocadlo DJ
    J Biol Chem; 2012 May; 287(19):15395-408. PubMed ID: 22311971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural insights into the substrate binding adaptability and specificity of human O-GlcNAcase.
    Li B; Li H; Hu CW; Jiang J
    Nat Commun; 2017 Sep; 8(1):666. PubMed ID: 28939839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. O-GlcNAcylation and neurodegeneration.
    Wani WY; Chatham JC; Darley-Usmar V; McMahon LL; Zhang J
    Brain Res Bull; 2017 Jul; 133():80-87. PubMed ID: 27497832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hijacking of the O-GlcNAcZYME complex by the HTLV-1 Tax oncoprotein facilitates viral transcription.
    Groussaud D; Khair M; Tollenaere AI; Waast L; Kuo MS; Mangeney M; Martella C; Fardini Y; Coste S; Souidi M; Benit L; Pique C; Issad T
    PLoS Pathog; 2017 Jul; 13(7):e1006518. PubMed ID: 28742148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased O-GlcNAc levels correlate with decreased O-GlcNAcase levels in Alzheimer disease brain.
    Förster S; Welleford AS; Triplett JC; Sultana R; Schmitz B; Butterfield DA
    Biochim Biophys Acta; 2014 Sep; 1842(9):1333-9. PubMed ID: 24859566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular Interrogation to Crack the Case of O-GlcNAc.
    Estevez A; Zhu D; Blankenship C; Jiang J
    Chemistry; 2020 Sep; 26(53):12086-12100. PubMed ID: 32207184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional significance of O-GlcNAc modification in regulating neuronal properties.
    Hwang H; Rhim H
    Pharmacol Res; 2018 Mar; 129():295-307. PubMed ID: 29223644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. O-GlcNAc processing enzymes: catalytic mechanisms, substrate specificity, and enzyme regulation.
    Vocadlo DJ
    Curr Opin Chem Biol; 2012 Dec; 16(5-6):488-97. PubMed ID: 23146438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. O-GlcNAc modification of tau directly inhibits its aggregation without perturbing the conformational properties of tau monomers.
    Yuzwa SA; Cheung AH; Okon M; McIntosh LP; Vocadlo DJ
    J Mol Biol; 2014 Apr; 426(8):1736-52. PubMed ID: 24444746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aberrant O-GlcNAc-modified proteins expressed in primary colorectal cancer.
    Phueaouan T; Chaiyawat P; Netsirisawan P; Chokchaichamnankit D; Punyarit P; Srisomsap C; Svasti J; Champattanachai V
    Oncol Rep; 2013 Dec; 30(6):2929-36. PubMed ID: 24126823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human OGA binds substrates in a conserved peptide recognition groove.
    Schimpl M; Schüttelkopf AW; Borodkin VS; van Aalten DM
    Biochem J; 2010 Nov; 432(1):1-7. PubMed ID: 20863279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. E. coli sabotages the in vivo production of O-linked β-N-acetylglucosamine-modified proteins.
    Goodwin OY; Thomasson MS; Lin AJ; Sweeney MM; Macnaughtan MA
    J Biotechnol; 2013 Dec; 168(4):315-23. PubMed ID: 24140293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.